Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma

Status unconfirmed · Phase 2

Conditions studied: Brain and Central Nervous System Tumors

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have recurrent or progressive malignant glioma.

Key facts

Study ID

NCT00004204

Run by

Herbert Irving Comprehensive Cancer Center

Starts

2000-02-01

Last updated by the study team

2014-01-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Stanford University Medical Center — Stanford, California, United States
• Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida, United States
• Robert H. Lurie Comprehensive Cancer Center, Northwestern University — Chicago, Illinois, United States
• Cancer Center of Albany Medical Center — Albany, New York, United States
• Herbert Irving Comprehensive Cancer Center — New York, New York, United States
• Nalitt Institute for Cancer And Blood Related Diseases — Staten Island, New York, United States
• Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio, United States
• Neurological Clinic — Portland, Oregon, United States
• University of Pennsylvania Cancer Center — Philadelphia, Pennsylvania, United States
• Froedtert Memorial Lutheran Hospital — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.